Price:

SCIENCE

Jeff Coller says mRNA-CRISPR convergence cures genetic disease

Thursday, June 18, 2026 · from 3 podcasts
MindscapePeter Attia DriveFreakonomics Radio
  • mRNA-CRISPR therapies already cured a baby of a fatal enzyme deficiency.
  • Manufacturing mRNA vaccines requires a bioreactor the size of a soda bottle.
  • AI scribes reverse the productivity paradox plaguing electronic health records.

A one-in-a-million genetic disease killed baby KJ Moldun. Researchers treated him with mRNA-based CRISPR, permanently correcting his liver DNA. Jeff Coller, a professor of RNA biology at Johns Hopkins, detailed the case on Sean Carroll's Mindscape.

The approach turns medicine into precision surgery. mRNA delivers the CRISPR tool into cells and then vanishes within hours. The transient nature is a safety feature. It prevents off-target mutations. Moldun is thriving, a proof-of-concept that researchers can rewrite human biology in vivo.

Manufacturing these treatments is software-like. Coller noted that during the 2019 outbreak, a graduate student designed the Moderna COVID-19 vaccine in hours by downloading the virus's genetic sequence. mRNA is synthesized in a test tube. A bioreactor the size of a 2-liter soda bottle can hold enough material to inoculate the entire planet.

"mRNA flips this model by making the patient’s own body the factory."

- Jeff Coller, Sean Carroll's Mindscape

Tropism remains the bottleneck. Lipid nanoparticles - the fat bubbles transporting mRNA - almost always end up in the liver. This leaves the brain, heart, and kidneys out of reach. Until researchers engineer delivery shells that navigate to specific organs, the most revolutionary cures will remain localized.

Advances in AI are reshaping adjacent parts of healthcare. Dr. Bob Wachter, speaking on Freakonomics Radio, described a system where doctors spend eight hours a week filling out charts at home. Ambient intelligence scribes now record visits and synthesize transcripts into formal notes. At UCSF, doctors are regaining the ability to look patients in the eye.

"That dynamic is shifting through 'ambient intelligence' scribes."

- Dr. Bob Wachter, Freakonomics Radio

The convergence of these technologies hints at a future where AI handles administrative sludge and bespoke genetic therapies treat the root cause of disease. Yet systemic execution failures persist. On The Peter Attia Drive, Attia noted that while 9% of women meet the threshold for supplemental breast MRI screening, only 0.4% receive it. The gap between technological possibility and clinical reality remains wide.

#Health#Longevity#Biology
CRISPR-Cas9

Source Intelligence

- Deep dive into what was said in the episodes

Sean Carroll's Mindscape
Sean Carroll's Mindscape

357 | Jeff Coller on mRNA, Vaccines, and Bespoke Therapeutics • Jun 15

  • The human genome contains about 25,000 genes, each producing its own mRNA. A single human cell houses roughly half a million ribosomes that decode these messages.
  • Coller notes RNA likely preceded DNA as Earth’s first genetic material because its extra oxygen enables catalytic chemistry and complex shapes, whereas DNA’s stability makes it a superior long-term information repository.
  • mRNA vaccines deploy faster and cheaper than traditional protein vaccines, as they skip the need for bioreactors and egg-based protein production, allowing design in hours and manufacturing in weeks.
  • Moderna’s lead designer Vlad Presnak created the COVID-19 vaccine sequence hours after China released the SARS-CoV-2 genome in January 2020, demonstrating the rapid in silico design potential of mRNA technology.
  • Delivery remains the central challenge for mRNA therapeutics; lipid nanoparticles effectively target immune cells at injection sites and the liver, but reaching organs like the brain, pancreas, or lungs requires new tropism solutions.
  • Combining CRISPR base editing with mRNA creates a transient surgical tool; the mRNA delivers the editing machinery, makes the DNA correction, and then degrades, leaving only the fixed genetic change.
  • This approach successfully treated baby KJ Moldun, born with CPS1 deficiency; researchers used mRNA-based CRISPR to correct his liver DNA, avoiding a liver transplant and demonstrating personalized therapy for ultra-rare disorders.
  • One in thirteen people suffers from a genetic disease. Bespoke genetic therapies could address over 7,000 disorders, but economic and regulatory models must adapt from blockbuster drugs to individualized treatments.
  • mRNA neoantigen vaccines show promise against cancers like pancreatic cancer; a 2022 Nature study reported a 50% response rate in a small trial, with survivors cancer-free six years later.
  • China now develops 46% of all mRNA-based vaccines, signaling a global shift. Coller argues preserving American mRNA infrastructure is vital for national defense and pandemic response.
Also from this episode: (4)

Biology (3)

  • Jeff Coller explains messenger RNA as an individual recipe copied from a DNA gene, traveling to a ribosome to be read and then actively destroyed, ensuring cells don’t repeatedly make the same protein.
  • The genetic code uses 64 three-letter codons to specify 20 amino acids, with redundancy - arginine has five synonymous codons - and special start (ATG for methionine) and stop codons. Francis Crick called this arrangement a frozen accident.
  • Coller's lab studies how codon choice influences translation speed, as the abundance of matching transfer RNA dictates how quickly a ribosome reads a codon, which in turn affects mRNA stability.

AI & Tech (1)

  • Coller warns AI-designed pathogens pose a serious threat, citing a study where AI created novel bacterial viruses outperforming natural ones. mRNA vaccine speed is our only viable countermeasure, making the technology a crucial deterrent.
#Health#Biology#Longevity
The Peter Attia Drive
The Peter Attia Drive

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy • Jun 15

Also from this episode: (15)

Health (15)

  • Peter Attia states breast cancer is the fourth-leading cause of cancer death after lung, colorectal, and pancreatic cancer.
  • Attia cites CISNET models showing annual mammography for women 40-79 yields a 42% mortality reduction versus 30% for biennial screening, translating to 230 life-years gained per 1,000 women annually versus 165 biennially.
  • Attia notes observational data shows women screening annually had an 11% interval cancer rate versus 38% for biennial screeners, and annual screening led to 76% stage one diagnoses versus 56% for biennial.
  • Attia argues aggressive cancers comprise 7-10% of cases, eluding even perfect screening, while underscreening is the larger, solvable problem.
  • Attia states about 20% of women 50-74 are not up-to-date on mammograms, and at least 9% qualify for MRI under guidelines but only 0.4% get it.
  • Attia recommends a formal risk assessment by age 25 to determine if you are truly average risk or need earlier, more intensive screening.
  • Attia says BRCA mutations occur in about 1 in 400 people overall but are more prevalent in Ashkenazi Jewish ancestry, while triple-negative cancers account for 20% of cases in women under 40 versus 6-12% in older women.
  • Attia notes breast cancer risk is cumulative; only about 5% of diagnoses occur under age 40, and cumulative risk through age 40 is less than 1%.
  • Attia cites a study of 6 million mammograms showing cancer detection rates: 2.1 per 1,000 for women 35-39 with risk factors versus 0.59 per 1,000 for average-risk women, and 0.71 per 1,000 for average-risk women 40-44.
  • Attia says triple-negative cancers can double in size in under four months, making annual screening insufficient for some high-risk younger women.
  • Attia states about 50% of screening-age women have dense breast tissue, which both raises baseline risk and reduces mammogram sensitivity.
  • Attia explains DCIS, found via mammography, has a 25-60% chance of progressing to invasive cancer, justifying its detection.
  • Attia notes adding MRI to mammography for dense breasts halved interval cancer rates from 5 per 1,000 to 2.5 per 1,000.
  • Attia cites studies showing handheld ultrasound added to 2D mammography increased detection by 4.2 per 1,000, while adding it to DBT only boosted detection by 1.1 per 1,000.
  • Attia argues inflammatory breast cancer accounts for 1-5% of cases, often lacks a discrete lump, and requires diagnostic workup as it may not appear on screening mammograms.
#Health#Longevity#Biology
Freakonomics Radio
Freakonomics Radio

677. Can Backgammon Save Us from Ourselves? • Jun 12

  • Pierre Elias says traditional cardiovascular disease detection via cardiac catheterization is too invasive for healthy patients, and echocardiograms are too expensive for population screening, creating a diagnostic gap.
  • Elias's AI model, EchoNet, analyzed ECGs from nearly 20,000 patients and predicted structural heart disease with 78% accuracy, outperforming cardiologists at 64%.
  • A Lancet study found gastroenterologists' colonoscopy performance declined after a three-month AI assist was removed, showing rapid deskilling even in experienced doctors.
Also from this episode: (12)

Business (4)

  • Bob Watcher says healthcare delivery remains sloppy due to high fixed costs, powerful incumbents, and a 'funky' economic model where customers don't directly choose vendors.
  • Watcher argues healthcare is the largest user of fax machines in the country and only recently ditched pagers after drug dealers did.
  • The transition from paper to digital records didn't transform medicine and in some ways made things worse, creating a 'productivity paradox' where technology failed to improve efficiency.
  • Watcher says billing creates perverse incentives, as reimbursement hinges on how a doctor phrases notes, not just the care provided.

Culture (1)

  • A 2012 JAMA crayon drawing by a seven-year-old captured the doctor-patient relationship breakdown, showing the doctor typing with his back turned.

AI & Tech (6)

  • AI scribes using ambient intelligence now summarize patient conversations, grouping related symptoms and filtering out personal anecdotes, which restores eye contact and reduces physician 'pajama time'.
  • Watcher cites a case where a human error - misinterpreting 'PE' for physical exam as pulmonary embolism - stuck in a patient's record for 20 years, arguing AI summarization can reduce such mistakes despite hallucination risks.
  • Watcher says Epic dominates the EHR market with records for 325 million people, winning through integrated solutions, but its closed system may slow AI innovation by locking out third-party tools.
  • Watcher argues FDA-style regulation isn't fit for most AI tools because they shape-shift and update constantly, unlike static drugs or devices, and that overregulation now poses a bigger risk than underregulation.
  • Watcher says patients in blinded trials often rated AI as more empathetic than doctors, though the AI is merely mimicking empathy effectively.
  • Watcher remains optimistic about AI in healthcare because the system is 'so screwed up' and can't afford to simply hire more humans, but success depends on culture, regulation, and workflow integration more than pure tech capability.

Health (1)

  • In the CACTUS trial, AI screening in eight New York emergency departments found half of high-risk patients for undiagnosed structural heart disease weren't getting follow-up echocardiograms.
#Health#Models#Enterprise#Regulation